Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1579-1583, 2023.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-1010009
Responsible library:
WPRO
ABSTRACT
BCR-ABLT315I mutation is the main mechanism of resistance to the first and second generation tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML). Ponatinib as the third generation TKI has been found that can significantly improve the prognosis of CML patients with T315I mutation. However, the latest report has discovered that the T315I compound mutant is even resistant to ponatinib, which aroused the enthusiasm of research on the mechanism of CML resistance and targeted therapy once again. Previous studies have shown that TKI combined with other targeted drugs is effective to CML patients with drug resistance or relapse due to T315I mutation. The latest research has found that the allosteric inhibitor asciminib combined with TKI therapy is equally effective to CML patients with T315I compound mutant, but the specific mechanism is not yet clarified. This review will focus on the latest research progress of therapy for CML with BCR-ABLT315I mutation, hoping to provide reference for researching new drugs and improve therapy for treating CML with T315I mutation.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Fusion Proteins, bcr-abl
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
Mutation
/
Antineoplastic Agents
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2023
Document type:
Article